India at a glance
- Population
- 1.46 billion 2025
- Life expectancy at birth
- 72.2 years, 2024
- People aged 65 and over
- 7.4 % of people, 2025
- Health spending per person
- 85 US$ per person, 2023
- Doctors
- 0.72 per 1,000 people, 2020
Updated
Reviewed by Vidhi Upadhyay
India Neuropathic Pain Treatment Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$193.9 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $173.6 Mn | — | — |
| 2025 (base) | $187.8 Mn | +$14.2 Mn | — |
| 2026 (forecast) | $203.2 Mn | +$15.4 Mn | +8.2% |
| 2027 (forecast) | $219.8 Mn | +$16.7 Mn | +17.1% |
| 2028 (forecast) | $237.9 Mn | +$18.0 Mn | +26.7% |
| 2029 (forecast) | $257.4 Mn | +$19.5 Mn | +37.1% |
| 2030 (forecast) | $278.5 Mn | +$21.1 Mn | +48.3% |
| 2031 (forecast) | $301.3 Mn | +$22.8 Mn | +60.5% |
| 2032 (forecast) | $326.0 Mn | +$24.7 Mn | +73.6% |
| 2033 (forecast) | $352.8 Mn | +$26.7 Mn | +87.9% |
| 2034 (forecast) | $381.7 Mn | +$28.9 Mn | +103.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $187.8 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $381.7 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 8.2% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Drug class, indication and end user (see all) |
| Key players | Pfizer Inc., Eli Lilly and Company, Vertex Pharmaceuticals, Grunenthal, Daiichi Sankyo Company (see all) |
| Regulator in India | CDSCOSource: Central Drugs Standard Control Organisation. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Neuropathic pain treatments ease pain from damaged nerves, such as in diabetes, shingles and spinal injury.
Key segments of the neuropathic Pain Treatment market include drug class (Anticonvulsants, Antidepressants and Topical Agents) and indication (Diabetic Neuropathy, Postherpetic Neuralgia and Spinal Cord Injury).
An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the neuropathic Pain Treatment market.
Biomarker-guided treatment, earlier diagnosis and new device-based therapies give the neuropathic Pain Treatment market strong room to grow.
Hard-to-reach brain targets, high failure rates in trials, side effects and high prices for new therapies hold back the neuropathic Pain Treatment market.
The neuropathic Pain Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
New drugs and clinical trials need approval from the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India.[1] Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year.[2]
[1] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
[2] National Health Authority (PM-JAY). Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for neuropathic Pain Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in India.
What doctors and scientists are doing in Neuropathic Pain Treatment right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.
From our blog
India · 2 shared keywords
India · 2 shared keywords
India · 1 shared keyword
India · 1 shared keyword
India · 1 shared keyword
India · 1 shared keyword
Medical Devices · India
Healthcare Services · India
Healthcare Services · India
Digital Health · India
Digital Health · India
Medical Devices · India